DexCom, Inc. (DXCM) Revenue CAGR:16.16%(TTM)
The revenue cagr for DexCom, Inc. (DXCM) is +16.16% over the latest trailing 12-month period. Revenue CAGR uses precomputed financial statement history.
The revenue CAGR for DexCom, Inc. (DXCM) stock is 16.16% over the past 12 months. The 3 year CAGR is 16.81% and the 5 year CAGR is 18.91%. Revenue CAGR measures how DexCom, Inc.'s top-line revenue has grown over time. Consistent revenue growth is a key indicator of business expansion and market share gains.
DXCM Revenue CAGR Chart
DexCom, Inc. (DXCM)
DXCM Quarterly Revenue Growth (YoY)
Revenue growth vs the same quarter one year earlier, last 20 quarters.
DXCM Revenue CAGR History
| Year | Start Revenue | End Revenue | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $4.03B | $4.66B | +$629.00M | +15.60% | +15.60% |
| 2024 | $3.62B | $4.03B | +$410.70M | +11.34% | +11.34% |
| 2023 | $2.91B | $3.62B | +$712.50M | +24.49% | +24.49% |
| 2022 | $2.45B | $2.91B | +$461.30M | +18.84% | +18.84% |
| 2021 | $1.93B | $2.45B | +$521.80M | +27.08% | +27.08% |
| 2020 | $1.48B | $1.93B | +$450.70M | +30.54% | +30.54% |
| 2019 | $1.03B | $1.48B | +$444.40M | +43.08% | +43.08% |
| 2018 | $718.50M | $1.03B | +$313.10M | +43.58% | +43.58% |
| 2017 | $573.30M | $718.50M | +$145.20M | +25.33% | +25.33% |
| 2016 | $402.00M | $573.30M | +$171.30M | +42.61% | +42.61% |
| 2015 | $259.20M | $402.00M | +$142.80M | +55.09% | +55.09% |
| 2014 | $160.00M | $259.20M | +$99.20M | +62.00% | +62.00% |
| 2013 | $99.90M | $160.00M | +$60.10M | +60.16% | +60.16% |
| 2012 | $76.27M | $99.90M | +$23.63M | +30.99% | +30.99% |
| 2011 | $48.63M | $76.27M | +$27.64M | +56.83% | +56.83% |
| 2010 | $29.69M | $48.63M | +$18.94M | +63.78% | +63.78% |
| 2009 | $9.84M | $29.69M | +$19.86M | +201.82% | +201.82% |
| 2008 | $4.63M | $9.84M | +$5.21M | +112.62% | +112.62% |
| 2007 | $2.17M | $4.63M | +$2.46M | +113.25% | +113.25% |
Quarterly Revenue: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q1 2026 | $1.19B | -5.4% | +15.0% |
| Q4 2025 | $1.26B | +4.2% | +13.1% |
| Q3 2025 | $1.21B | +4.5% | +21.6% |
| Q2 2025 | $1.16B | +11.7% | +15.2% |
| Q1 2025 | $1.04B | -7.0% | +12.5% |
| Q4 2024 | $1.11B | +12.0% | +7.6% |
| Q3 2024 | $994.20M | -1.0% | +2.0% |
| Q2 2024 | $1.00B | +9.0% | +15.3% |
| Q1 2024 | $921.00M | -11.0% | +24.2% |
| Q4 2023 | $1.03B | +6.1% | +26.9% |
| Q3 2023 | $975.00M | +11.9% | +26.7% |
| Q2 2023 | $871.30M | +17.5% | +25.2% |
| Q1 2023 | $741.50M | -9.0% | +17.9% |
| Q4 2022 | $815.20M | +5.9% | +16.8% |
| Q3 2022 | $769.60M | +10.5% | +18.4% |
| Q2 2022 | $696.20M | +10.7% | +17.0% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About DexCom, Inc.
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Jacob Steven Leach